Pfizer currently offers an annualized dividend yield of approximately 6.8%, one of the highest in the large-cap pharmaceutical sector. The company has maintained a quarterly payout of $0.40 per share for the past four distributions, representing a 5% compound annual growth rate in dividends over the last three years. With a payout ratio near 60% of adjusted earnings, Pfizer’s distribution level remains sustainable even after absorbing recent headwinds to sales.

Following a steep decline—nearly 50% year-over-year—in COVID-related product revenues since mid-2024, Pfizer’s total revenues normalized to approximately $18 billion in the fourth quarter. Management has redirected R&D resources into its oncology and rare disease franchises, with 12 phase III trials expected to read out in 2026. Notably, the experimental bispecific antibody targeting solid-tumor antigens could generate peak annual sales in excess of $1.5 billion if approved.

Pfizer will host a live webcast of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, beginning at 9:45 a.m. PST. Albert Bourla, Chairman and Chief Executive Officer, will discuss strategic priorities including capital allocation, upcoming regulatory milestones, and plans for share repurchases. The live stream and replay will be accessible on Pfizer’s investor relations website within 24 hours of the event and remain available for 90 days, providing transparent insight into management’s guidance for 2026.